These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 28267838)

  • 1. Cancer Center Launched Within FDA.
    Voelker R
    JAMA; 2017 Mar; 317(9):900. PubMed ID: 28267838
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of the FDA in cancer therapy research.
    Young RS
    Semin Oncol; 1981 Dec; 8(4):447-52. PubMed ID: 7323818
    [No Abstract]   [Full Text] [Related]  

  • 3. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. State of the center, CAM use in cancer patients, and initiatives with the FDA are topics of 14th NACCAM meeting.
    Le Tourneau M
    Altern Ther Health Med; 2003; 9(4):18. PubMed ID: 12868248
    [No Abstract]   [Full Text] [Related]  

  • 5. Cancer clinical trials: what is the impact of regulatory changes?
    Kearsey L
    ONS News; 2002 Sep; 17(9):1, 4-5. PubMed ID: 12244866
    [No Abstract]   [Full Text] [Related]  

  • 6. Cancer clinical trials in the USA: patient eligibility, generalizability of results and technology transfer.
    Begg CB
    Bull Cancer; 1987; 74(2):197-203. PubMed ID: 3607303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The placebo control in clinical trials (a view from the FDA).
    Leber P
    Psychopharmacol Bull; 1986; 22(1):30-2. PubMed ID: 3726077
    [No Abstract]   [Full Text] [Related]  

  • 8. Pain palliation measurement in cancer clinical trials: the US Food and Drug Administration perspective.
    Basch E; Trentacosti AM; Burke LB; Kwitkowski V; Kane RC; Autio KA; Papadopoulos E; Stansbury JP; Kluetz PG; Smith H; Justice R; Pazdur R
    Cancer; 2014 Mar; 120(5):761-7. PubMed ID: 24375398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growing Number of States Enact Right-to-Try Laws in Challenge to FDA.
    Wald A
    ONS Connect; 2016 Jan; 31(1):21. PubMed ID: 26887104
    [No Abstract]   [Full Text] [Related]  

  • 10. How to access and process FDA drug approval packages for use in research.
    Turner EH
    BMJ; 2013 Oct; 347():f5992. PubMed ID: 24126858
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA launches "new use initiative".
    Nat Biotechnol; 1997 May; 15(5):399. PubMed ID: 9131604
    [No Abstract]   [Full Text] [Related]  

  • 12. Issues in clinical trial design from the FDA perspective.
    Katz R
    Epilepsia; 2003; 44 Suppl 7():9-15. PubMed ID: 12919333
    [No Abstract]   [Full Text] [Related]  

  • 13. Industry, FDA warm to "adaptive" trials.
    Kuehn BM
    JAMA; 2006 Oct; 296(16):1955-7. PubMed ID: 17062852
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA signals it's open to drug trials that shift midcourse.
    Mathews AW
    Wall St J (East Ed); 2006 Jul; ():B1, B8. PubMed ID: 16858817
    [No Abstract]   [Full Text] [Related]  

  • 15. Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.
    Khin NA; Yang P; Hung HM; Maung-U K; Chen YF; Meeker-O'Connell A; Okwesili P; Yasuda SU; Ball LK; Huang SM; O'Neill RT; Temple R
    Clin Pharmacol Ther; 2013 Aug; 94(2):230-42. PubMed ID: 23588316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The United States Food and Drug Administration guidelines on ambulatory blood pressure monitoring.
    Lipicky R
    J Hypertens Suppl; 1991 Dec; 9(8):S59. PubMed ID: 1795204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should the FDA be the doctor of last resort?
    DeVita VT
    Nat Clin Pract Oncol; 2005 Sep; 2(9):423. PubMed ID: 16264991
    [No Abstract]   [Full Text] [Related]  

  • 18. The credibility of the FDA.
    Blankfield RP
    Eur J Prev Cardiol; 2013 Dec; 20(6):992-4. PubMed ID: 23867140
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA perspective on clinical trial design for cardiovascular devices.
    Chen E; Sapirstein W; Ahn C; Swain J; Zuckerman B
    Ann Thorac Surg; 2006 Sep; 82(3):773-5. PubMed ID: 16928481
    [No Abstract]   [Full Text] [Related]  

  • 20. Research infrastructure and IRB/FDA requirements.
    Cohen J
    Med Health R I; 2000 Dec; 83(12):382-5. PubMed ID: 11190124
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.